Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 11.

Koelzer, V H; Glatz, K; Bubendorf, L; Weber, A; Gaspert, A; Cathomas, G; Lugli, A; Zippelius, A; Kempf, W; Mertz, K D (2017). Pathologie der Nebenwirkungen von Immune-Checkpoint-Inhibitoren. Der Pathologe, 38(3):1-12.

Rothschild, S I; Zippelius, A; Prince, S Savic; Gonzalez, M; Weder, W; Xyrafas, A; Rusterholz, C; Pless, M (2016). 129TiP: SAKK 16/14 - anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC): a multicenter single-arm phase II trial. Journal of Thoracic Oncology, 11(4 Suppl):S112.

Burckhart, T; Thiel, M A; Nishikawa, H; Wüest, T; Müller, D; Zippelius, A; Ritter, G; Old, L; Shiku, H; Renner, C (2010). Tumor-specific crosslinking of GITR as costimulation for immunotherapy. Journal of Immunotherapy, 33(9):925-934.

Speiser, D E; Schwarz, K; Baumgaertner, P; Conzett, K B; Manolova, V; Devevre, E; Sterry, W; Walden, P; Zippelius, A; Senti, G; Voelter, V; Cerottini, J P; Guggisberg, D; Willers, J; Geldhof, C; Romero, P; Kündig, T; Knuth, A; Dummer, R; Trefzer, U; Bachmann, M F (2010). Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. Journal of Immunotherapy, 33(8):848-858.

Renner, C; Zippelius, A; Riethmüller, G; Knuth, A (2010). Tumorimmunologie. In: Hiddemann, W; Bartram, C R. Die Onkologie. Berlin, Deutschland: Springer Medizin Verlag, 325-345.

Knights, A J; Nuber, N; Thomson, C W; de la Rosa, O; Jäger, E; Tiercy, J M; van den Broek, Maries; Pascolo, S; Knuth, A; Zippelius, A (2009). Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients. Cancer Immunology, Immunotherapy, 58(3):325-338.

Tinguely, M; Jenni, B; Knights, A; Lopes, B; Korol, D; Rousson, V; Curioni Fontecedro, A; Cogliatti, S B; Bittermann, A G; Schmid, U; Dommann-Scherrer, C; Maurer, R; Renner, C; Probst-Hensch, N M; Moch, H; Knuth, A; Zippelius, A (2008). MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome. Cancer Science, 99(4):720-725.

Curioni-Fontecedro, A; Knights, A J; Tinguely, M; Nuber, N; Schneider, C; Thomson, C W; von Boehmer, I; Bossart, W; Pahlich, S; Gehring, H; Moch, H; Renner, C; Knuth, A; Zippelius, A (2008). MAGE-C1/CT7 is the dominant cancer-testis antigen targeted by humoral immune responses in patients with multiple myeloma. Leukemia, 22(8):1646-1648.

Theurillat, J P; Ingold, F; Freitag, C; Zippelius, A; Varga, Z; Seifert, Burkhardt; Chen, Y T; Jäger, D; Knuth, A; Moch, H (2007). NY-ESO-1 protein expression in primary breast carcinoma and metastases - correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration. International Journal of Cancer, 120(11):2411-2417.

Stenner-Liewen, F; Zippelius, A; Pestalozzi, B C; Knuth, A (2006). Molekular zielgerichtete Therapie. Der Chirurg, 77(12):1118-1125.

Trojan, A; Tinguely, M; Vallet, S; Seifert, Burkhardt; Jenni, B; Zippelius, A; Witzens-Harig, M; Mechtersheimer, G; Ho, A; Goldschmidt, H; Jäger, D; Boccadoro, M; Ladetto, M (2006). Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma. Swiss Medical Weekly, 136(25-26):400-403.

This list was generated on Mon Jun 17 15:06:43 2019 CEST.